Following on from information provided to NICE by the company in June 2022, the appraisal of Nivolumab for neoadjuvant and adjuvant treatment of localised renal cell carcinoma [ID4047] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | STA Standard |
| ID number | 4047 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 02 June 2023 | Discontinued. Following on from information provided to NICE by the company in June 2022, the appraisal of Nivolumab for neoadjuvant and adjuvant treatment of localised renal cell carcinoma [ID4047] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 28 June 2022 | Suspended. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes. |
For further information on our processes and methods, please see our CHTE processes and methods manual